USE OF A PHARMACEUTICAL COMPOSITION CONTAINING EPIDERMAL GROWTH FACTOR (EGF) FOR DIABETIC FOOT AMPUT

文件类型：PDF文档
文件大小：320K
Use of epidermal growth factor (EGF) in a composition for treating a lesion, ischemic or caused by reperfusion, in a diabetic patient, by local infiltration into the tissues that form the borders and base of the lesion, is new. An independent claim is also included for a pharmaceutical composition (liquid or freeze-dried) for treating the specified lesions that contains 10-1000 Microg/ml of EGF combined with at least one of fibronectin; raffinose; poly(ethyleneimine); an isoflavonoid (e.g. rutin); lidocaine; adenosine or guanosine triphosphates, or their salts; nicotinamide; L-Arg or heparin salt. ACTIVITY : Antidiabetic; Vulnerary. MECHANISM OF ACTION : Stimulation of cell proliferation.